ABCL Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$6.06 |
| 52 Week Low | US$2.34 |
| Beta | 0.41 |
| 1 Month Change | 3.26% |
| 3 Month Change | 14.92% |
| 1 Year Change | -49.91% |
| 3 Year Change | -80.91% |
| 5 Year Change | n/a |
| Change since IPO | -95.16% |
Recent News & Updates
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 07
AbCellera: A Platform To Pipeline Transition
Oct 14Recent updates
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 07AbCellera: A Platform To Pipeline Transition
Oct 14AbCellera: A Waiting Game With High Uncertainty
Aug 23Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11Shareholder Returns
| ABCL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.4% | -2.1% | -2.4% |
| 1Y | -49.9% | -5.5% | 23.4% |
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned -5.5% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABCL's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 586 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
AbCellera Biologics Inc. Fundamentals Summary
| ABCL fundamental statistics | |
|---|---|
| Market cap | US$841.79m |
| Earnings (TTM) | -US$175.80m |
| Revenue (TTM) | US$32.96m |
25.5x
P/S Ratio-4.8x
P/E RatioIs ABCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCL income statement (TTM) | |
|---|---|
| Revenue | US$32.96m |
| Cost of Revenue | US$169.81m |
| Gross Profit | -US$136.84m |
| Other Expenses | US$38.95m |
| Earnings | -US$175.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | -415.15% |
| Net Profit Margin | -533.33% |
| Debt/Equity Ratio | 0% |
How did ABCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AbCellera Biologics Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Antonia Borovina | Bloom Burton & Co. |
| David Martin | Bloom Burton & Co. |